Abhishek Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Abhishek Kumar has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Vivek Vasdev
Commandant, Military Hospital Bhopal, MP, India
4 shared publications Arun Hegde
Departments of Rheumatology Army Hospital Research and Referral, Delhi, India
3 shared publicationsHarsh Jain
3 shared publications- Sivasami Kartik
Department of Rheumatology, Army Hospital Research and Referral, New Delhi, Delhi, India
3 shared publications - Arun Hegde
Department of Medicine and Rheumatology, Military Hospital , Belagavi, Karnataka
2 shared publications Ashish Chandwani
2 shared publications
Latest Publications
- 10 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (5) , e70233
Intractable Thigh Pain due to Active Vasculitis in Femoral Arteries in Takayasu Arteritis
- 10 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (5) , e70233
Intractable Thigh Pain due to Active Vasculitis in Femoral Arteries in Takayasu Arteritis
- 29 July 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (7) , e259311-5
Paradoxical development of Kimura’s disease in a patient treated with mepolizumab for bronchial asthma
A male patient in his early 30s was diagnosed with bronchial asthma 3 years previously. He responded well to inhaled corticosteroids and long-acting beta-agonists. Approximately 18 months from the onset, the patient reported worsening symptoms. These symptoms included severe functional limitations, requiring frequent exposure to high-dose prednisolone. Mepolizumab was added to the treatment, leading to optimal control of bronchial asthma. Despite receiving seven doses of mepolizumab at monthly intervals, the patient developed cervical and postauricular lymphadenopathy and subcutaneous swelling of soft tissue. A cervical lymph node biopsy confirmed the diagnosis of Kimura disease. Following treatment with oral glucocorticoids and methotrexate, the patient experienced a complete resolution of symptoms. He has been in remission and off oral prednisolone for the last 13 months. In this case, we highlight the development of Kimura disease in a patient undergoing mepolizumab treatment.
- 29 July 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (7) , e259311-5
Paradoxical development of Kimura’s disease in a patient treated with mepolizumab for bronchial asthma
A male patient in his early 30s was diagnosed with bronchial asthma 3 years previously. He responded well to inhaled corticosteroids and long-acting beta-agonists. Approximately 18 months from the onset, the patient reported worsening symptoms. These symptoms included severe functional limitations, requiring frequent exposure to high-dose prednisolone. Mepolizumab was added to the treatment, leading to optimal control of bronchial asthma. Despite receiving seven doses of mepolizumab at monthly intervals, the patient developed cervical and postauricular lymphadenopathy and subcutaneous swelling of soft tissue. A cervical lymph node biopsy confirmed the diagnosis of Kimura disease. Following treatment with oral glucocorticoids and methotrexate, the patient experienced a complete resolution of symptoms. He has been in remission and off oral prednisolone for the last 13 months. In this case, we highlight the development of Kimura disease in a patient undergoing mepolizumab treatment.
- 29 April 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (4) , e258688
Bilateral Takayasu’s retinopathy as the initial presentation of Takayasu’s arteritis
We present a case of Takayasu’s arteritis in a woman in her 30s, who exhibited visual symptoms and ophthalmic manifestations of the disease, specifically Takayasu’s retinopathy stage 4, in both eyes. Despite severe narrowing of all branches of the aortic arch and compromised perfusion in both upper limbs, she had no history of intermittent claudication. Doppler study and CT angiography revealed diffuse circumferential wall thickening of bilateral common carotid, subclavian and axillary arteries. Treatment involved retinal laser photocoagulation and immune suppression. This case underscores that advanced Takayasu’s retinopathy can be an initial presentation of Takayasu’s arteritis even in a state of severely compromised peripheral limb circulation.
- 29 April 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (4) , e258688
Bilateral Takayasu’s retinopathy as the initial presentation of Takayasu’s arteritis
We present a case of Takayasu’s arteritis in a woman in her 30s, who exhibited visual symptoms and ophthalmic manifestations of the disease, specifically Takayasu’s retinopathy stage 4, in both eyes. Despite severe narrowing of all branches of the aortic arch and compromised perfusion in both upper limbs, she had no history of intermittent claudication. Doppler study and CT angiography revealed diffuse circumferential wall thickening of bilateral common carotid, subclavian and axillary arteries. Treatment involved retinal laser photocoagulation and immune suppression. This case underscores that advanced Takayasu’s retinopathy can be an initial presentation of Takayasu’s arteritis even in a state of severely compromised peripheral limb circulation.
- Open Access
- 1 January 2022
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 9 (1) , 26-30
Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study
Objective: There is no clinically useful biomarker as a predictor of response to any class of biological disease-modifying antirheumatic drugs (bDMARD). Serum interleukin-6 (IL-6) has a major role in the pathogenesis of rheumatoid arthritis (RA) and its serum level in patients of RA may predict response to treatment with IL-6 receptor (IL-6R) antagonist tocilizumab. Methods: Biological DMARD naïve patients of seropositive RA, fulfilling American College of Rheumatology/European League Against Rheumatism classification criteria 2010, were treated with 06 doses of tocilizumab (8mg/kg) at monthly interval. Baseline and post-treatment serum IL-6 levels were measured and correlated with response to treatment measured by disease activity score-28 joints erythrocyte sedimentation rate (DAS28 ESR) after treatment. Results: The study included 34 patients and 26 (70%) of them achieved DAS-28 remission (DAS28 ESR < 2.6). The baseline serum IL-6 did not correlate with post-treatment DAS28 ESR (R −0.197, P = .264). Though, statistically not significant (P = .085) more patients with comparatively lower baseline serum IL-6 attained DAS28 remission (16 out of 17, P = .085). There was an increase in the serum IL-6 level (median 40.5pg/ml [IQR 130.2] to 72.6pg/ml [IQR 162.5]) after tocilizumab treatment and the change in IL-6 level also did not correlate with post-treatment DAS28 ESR (R −0.240, P = .172). Conclusion: Higher number of patients with comparatively lower serum IL-6 level attained DAS28 remission in this study; however, it was not statistically significant. It requires further evaluation in larger studies to make any conclusion on the role of serum IL-6 as a predictor of response to tocilizumab in seropositive RA. Cite this article as: Kumar A, Bhakuni DS, Kartik S, et al. Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study. Eur J Rheumatol. 2021;9(1):26-30.
- 1 January 2022
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 9 (1) , 26-30
Open AccessSerum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study
Objective: There is no clinically useful biomarker as a predictor of response to any class of biological disease-modifying antirheumatic drugs (bDMARD). Serum interleukin-6 (IL-6) has a major role in the pathogenesis of rheumatoid arthritis (RA) and its serum level in patients of RA may predict response to treatment with IL-6 receptor (IL-6R) antagonist tocilizumab. Methods: Biological DMARD naïve patients of seropositive RA, fulfilling American College of Rheumatology/European League Against Rheumatism classification criteria 2010, were treated with 06 doses of tocilizumab (8mg/kg) at monthly interval. Baseline and post-treatment serum IL-6 levels were measured and correlated with response to treatment measured by disease activity score-28 joints erythrocyte sedimentation rate (DAS28 ESR) after treatment. Results: The study included 34 patients and 26 (70%) of them achieved DAS-28 remission (DAS28 ESR < 2.6). The baseline serum IL-6 did not correlate with post-treatment DAS28 ESR (R −0.197, P = .264). Though, statistically not significant (P = .085) more patients with comparatively lower baseline serum IL-6 attained DAS28 remission (16 out of 17, P = .085). There was an increase in the serum IL-6 level (median 40.5pg/ml [IQR 130.2] to 72.6pg/ml [IQR 162.5]) after tocilizumab treatment and the change in IL-6 level also did not correlate with post-treatment DAS28 ESR (R −0.240, P = .172). Conclusion: Higher number of patients with comparatively lower serum IL-6 level attained DAS28 remission in this study; however, it was not statistically significant. It requires further evaluation in larger studies to make any conclusion on the role of serum IL-6 as a predictor of response to tocilizumab in seropositive RA. Cite this article as: Kumar A, Bhakuni DS, Kartik S, et al. Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study. Eur J Rheumatol. 2021;9(1):26-30.
- Open Access
- 1 July 2021
- Published by Elsevier in Medical Journal Armed Forces India
- Vol. 77 (Suppl 2) , S296-S304
A single-center experience in use of tocilizumab in COVID-19 pneumonia in India
- 1 July 2021
- Published by Elsevier in Medical Journal Armed Forces India
- Vol. 77 (Suppl 2) , S296-S304
Open AccessA single-center experience in use of tocilizumab in COVID-19 pneumonia in India
- Open Access
- 1 March 2020
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 15 (1) , 56-58
TEN in a Case of SLE - A Case Based Review
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder of unknown etiology. Cutaneous manifestations in SLE are common, results in significant morbidity and helpful in diagnosis of underlying systemic disease. Vesiculobullous lesions in SLE are uncommon but present a diagnostic challenge. It can be a manifestation of SLE-specific or nonspecific pathology. It can also result from unrelated etiology such as drug-induced toxic epidermal necrolysis (TEN). Clinically, it is challenging to differentiate TEN-like acute cutaneous lupus erythematosus from classical TEN. We hereby present a case of TEN in SLE and discuss approach to vesiculobullous lesions in SLE.
- 1 March 2020
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 15 (1) , 56-58
Open AccessTEN in a Case of SLE - A Case Based Review
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder of unknown etiology. Cutaneous manifestations in SLE are common, results in significant morbidity and helpful in diagnosis of underlying systemic disease. Vesiculobullous lesions in SLE are uncommon but present a diagnostic challenge. It can be a manifestation of SLE-specific or nonspecific pathology. It can also result from unrelated etiology such as drug-induced toxic epidermal necrolysis (TEN). Clinically, it is challenging to differentiate TEN-like acute cutaneous lupus erythematosus from classical TEN. We hereby present a case of TEN in SLE and discuss approach to vesiculobullous lesions in SLE.
- Open Access
- 1 December 2018
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 13 (4) , 246-251
Assessment of Hepatic Fibrosis in Patients with Rheumatoid Arthritis on Long-term Methotrexate Therapy Using Transient Elastography
Background: Methotrexate (MTX) is has been associated with hepatotoxicity including hepatic fibrosis; however, the incidence of severe hepatic fibrosis or cirrhosis with MTX use has remained a controversial issue. The gold standard test for detecting liver fibrosis has been a liver biopsy, which is an invasive procedure with potentially serious complications. The transient elastography (TE) is a noninvasive method of assessing hepatic fibrosis. The primary objective of this study was to assess the prevalence of hepatic fibrosis associated with long-term MTX therapy in patients with RA and the secondary objective was to assess the correlation of cumulative MTX dose with hepatic fibrosis as assessed by TE using Fibroscan. Methods: In this cross-sectional study patients with RA who had been on MTX treatment for >5 years were included. Hepatic fibrosis was determined by measuring the hepatic stiffness by TE method (by FibroScan) in kilopascal (kPa) in study patients. The hepatic stiffness of the patient group was compared with that of healthy controls. Results: A total of 160 patients and 63 healthy controls were included in the study. The mean age of the patients was 51±10.9 years and there were 139 female and 21 male patients.The median duration of MTX use was 317.5 weeks (range 260, 1302 years). Median MTX cumulative dose was 4225 mg (range 2340, 18,200 mg). Mean hepatic stiffness was 4.8 kPa (SD 1.35) in the patient group and 4.7 kPa (SD 1.07) in the control group (P = 0.550). Cumulative dose or duration of MTX treatment did not correlate with hepatic fibrosis. Conclusions: Severe hepatic fibrosis or cirrhosis as detected by the TE using Fibroscan was uncommon with high cumulative dose of MTX when administered in the low-dose weekly schedule. The cumulative dose of MTX did not correlate with hepatic fibrosis as assessed by FibroScan.
- 1 December 2018
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 13 (4) , 246-251
Open AccessAssessment of Hepatic Fibrosis in Patients with Rheumatoid Arthritis on Long-term Methotrexate Therapy Using Transient Elastography
Background: Methotrexate (MTX) is has been associated with hepatotoxicity including hepatic fibrosis; however, the incidence of severe hepatic fibrosis or cirrhosis with MTX use has remained a controversial issue. The gold standard test for detecting liver fibrosis has been a liver biopsy, which is an invasive procedure with potentially serious complications. The transient elastography (TE) is a noninvasive method of assessing hepatic fibrosis. The primary objective of this study was to assess the prevalence of hepatic fibrosis associated with long-term MTX therapy in patients with RA and the secondary objective was to assess the correlation of cumulative MTX dose with hepatic fibrosis as assessed by TE using Fibroscan. Methods: In this cross-sectional study patients with RA who had been on MTX treatment for >5 years were included. Hepatic fibrosis was determined by measuring the hepatic stiffness by TE method (by FibroScan) in kilopascal (kPa) in study patients. The hepatic stiffness of the patient group was compared with that of healthy controls. Results: A total of 160 patients and 63 healthy controls were included in the study. The mean age of the patients was 51±10.9 years and there were 139 female and 21 male patients.The median duration of MTX use was 317.5 weeks (range 260, 1302 years). Median MTX cumulative dose was 4225 mg (range 2340, 18,200 mg). Mean hepatic stiffness was 4.8 kPa (SD 1.35) in the patient group and 4.7 kPa (SD 1.07) in the control group (P = 0.550). Cumulative dose or duration of MTX treatment did not correlate with hepatic fibrosis. Conclusions: Severe hepatic fibrosis or cirrhosis as detected by the TE using Fibroscan was uncommon with high cumulative dose of MTX when administered in the low-dose weekly schedule. The cumulative dose of MTX did not correlate with hepatic fibrosis as assessed by FibroScan.
- Open Access
- 1 November 2018
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 13 (3) , 163-167
Safety and Efficacy of Abatacept among Patients with Refractory Rheumatoid Arthritis: Experience from a North Indian Tertiary Care Hospital
Background: T-cells are pathogenic in rheumatoid arthritis (RA) and have an important role in persistent synovitis, even in established disease. Modulation of T-cell activity by blocking of costimulatory signals has been known to suppress inflammation and improves prognosis in RA. This study aims to assess the effect of costimulation blockade with Abatacept in patients with RA who were refractory to conventional synthetic/biological disease modifying anti-rheumatoid drugs (csDMARDs, bDMARDs). Methods: In this prospective study, 63 patients with active disease, measured by the European League Against Rheumatism (EULAR) disease activity score (DAS28-erythrocyte sedimentation rate [ESR]) ≥3.2, who had failed conventional therapy with at least 2 csDMARDs and/or antitumour necrosis factor (anti-TNF) agents (Infliximab/Etanercept) either standalone, or in combination, were initiated on Abatacept in fixed doses, which was given on days 1,15, and 29 and repeated every 28 days for 11 months, after taking informed consent. Biomarkers comprising ESR and DAS28-ESR score were measured at baseline and repeated at the end of 3, 6, and 12 months. The primary end-point was the achievement of remission as defined by DAS28-ESR score ≤ 2.6. Results: Sixty-three patients completed 6 monthly follow-up whereas 57 patients completed 12 months follow-up (90% follow-up rate). DAS28-ESR declined significantly at 3 months (P = 0) and improvements were sustained at 6th and 12th month. Treatment was discontinued in three patients due to inadequate response, and three patients were lost to follow-up. Nearly 52.6% patients achieved primary end-point. Most common adverse effects reported during the study period were headache (14.2%) and upper respiratory tract infection (9.5%). Conclusions: Abatacept is an effective and well-tolerated treatment option for Indian RA patients with an inadequate response to csDMARDs and TNF antagonists.
- 1 November 2018
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 13 (3) , 163-167
Open AccessSafety and Efficacy of Abatacept among Patients with Refractory Rheumatoid Arthritis: Experience from a North Indian Tertiary Care Hospital
Background: T-cells are pathogenic in rheumatoid arthritis (RA) and have an important role in persistent synovitis, even in established disease. Modulation of T-cell activity by blocking of costimulatory signals has been known to suppress inflammation and improves prognosis in RA. This study aims to assess the effect of costimulation blockade with Abatacept in patients with RA who were refractory to conventional synthetic/biological disease modifying anti-rheumatoid drugs (csDMARDs, bDMARDs). Methods: In this prospective study, 63 patients with active disease, measured by the European League Against Rheumatism (EULAR) disease activity score (DAS28-erythrocyte sedimentation rate [ESR]) ≥3.2, who had failed conventional therapy with at least 2 csDMARDs and/or antitumour necrosis factor (anti-TNF) agents (Infliximab/Etanercept) either standalone, or in combination, were initiated on Abatacept in fixed doses, which was given on days 1,15, and 29 and repeated every 28 days for 11 months, after taking informed consent. Biomarkers comprising ESR and DAS28-ESR score were measured at baseline and repeated at the end of 3, 6, and 12 months. The primary end-point was the achievement of remission as defined by DAS28-ESR score ≤ 2.6. Results: Sixty-three patients completed 6 monthly follow-up whereas 57 patients completed 12 months follow-up (90% follow-up rate). DAS28-ESR declined significantly at 3 months (P = 0) and improvements were sustained at 6th and 12th month. Treatment was discontinued in three patients due to inadequate response, and three patients were lost to follow-up. Nearly 52.6% patients achieved primary end-point. Most common adverse effects reported during the study period were headache (14.2%) and upper respiratory tract infection (9.5%). Conclusions: Abatacept is an effective and well-tolerated treatment option for Indian RA patients with an inadequate response to csDMARDs and TNF antagonists.
- Open Access
- 1 March 2018
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 13 (1) , 20-25
Safety and Efficacy of an Anti-CD20 Monoclonal Antibody (RedituxTM) In Indian Patients with Seropositive Rheumatoid Arthritis
Background: Rituximab (RTX), an anti-CD 20 monoclonal antibody is one of the first line biological disease-modifying anti-rheumatoid drug indicated for the treatment of rheumatoid arthritis (RA) in patient's refractory to conventional Synthetic DMARDs (csDMARDs). Limited data are available about the safety and efficacy of biosimilar version of this molecule. In this study, we assessed the clinical efficacy and safety profile of biosimilar RTX, RedituxTM. Methods: In this prospective study, 36 adults with moderate disease activity measured by the European League Against Rheumatism (EULAR) disease activity score (DAS28-erythrocyte sedimentation rate [ESR] ≥3.2), who had failed conventional therapy with at least 2 csDMARDs were initiated on RTX, 1000 mg, given on day 0 and day 15, after taking informed consent. Biomarkers including ESR, C reactive protein, Immunoglobulin G and M (IgG, IgM) and DAS28-ESR scores were measured at baseline and repeated at 2, 4, 8, 12, 16, 20, and 24 weeks. The primary endpoint was attaining EULAR good/moderate response. Results: DAS28-ESR score showed a statistically significant decline at 24 weeks (P < 0.001). Seventy-five percent patients showed an EULAR moderate response while 25% showed no EULAR response at 24 weeks posttreatment. IgG and IgM levels declined by 24.9% (P < 0.001) and 37% (P = 0.020) at end of 24 wks. However, there were no infections noted during the period of study. The most common adverse event was infusion reaction seen in 16.6% of patients. Conclusions: RTX is a safe and effective drug for the management of seropositive RA with results comparable with the original molecule. No serious adverse effects were noted in the study except for mild infusion reactions and fall in immunoglobulin levels.
- 1 March 2018
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 13 (1) , 20-25
Open AccessSafety and Efficacy of an Anti-CD20 Monoclonal Antibody (RedituxTM) In Indian Patients with Seropositive Rheumatoid Arthritis
Background: Rituximab (RTX), an anti-CD 20 monoclonal antibody is one of the first line biological disease-modifying anti-rheumatoid drug indicated for the treatment of rheumatoid arthritis (RA) in patient's refractory to conventional Synthetic DMARDs (csDMARDs). Limited data are available about the safety and efficacy of biosimilar version of this molecule. In this study, we assessed the clinical efficacy and safety profile of biosimilar RTX, RedituxTM. Methods: In this prospective study, 36 adults with moderate disease activity measured by the European League Against Rheumatism (EULAR) disease activity score (DAS28-erythrocyte sedimentation rate [ESR] ≥3.2), who had failed conventional therapy with at least 2 csDMARDs were initiated on RTX, 1000 mg, given on day 0 and day 15, after taking informed consent. Biomarkers including ESR, C reactive protein, Immunoglobulin G and M (IgG, IgM) and DAS28-ESR scores were measured at baseline and repeated at 2, 4, 8, 12, 16, 20, and 24 weeks. The primary endpoint was attaining EULAR good/moderate response. Results: DAS28-ESR score showed a statistically significant decline at 24 weeks (P < 0.001). Seventy-five percent patients showed an EULAR moderate response while 25% showed no EULAR response at 24 weeks posttreatment. IgG and IgM levels declined by 24.9% (P < 0.001) and 37% (P = 0.020) at end of 24 wks. However, there were no infections noted during the period of study. The most common adverse event was infusion reaction seen in 16.6% of patients. Conclusions: RTX is a safe and effective drug for the management of seropositive RA with results comparable with the original molecule. No serious adverse effects were noted in the study except for mild infusion reactions and fall in immunoglobulin levels.